| Title |
Progesterone receptor variants found in breast cells repress transcription by wild-type receptors
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, April 1998
|
| DOI | 10.1023/a:1005941117247 |
| Pubmed ID | |
| Authors |
J.K. Richer, C.A. Lange, A.M. Wierman, K.M. Brooks, L. Tung, G.S. Takimoto, K.B. Horwitz |
| Abstract |
Progesterone, through its nuclear receptors (PR), regulates the development and growth of breast cancers. PR also serve as markers of hormone dependence and prognosis in patients with this disease, and functional PR are required to mediate the antiproliferative effects of progestin therapies. We find that normal and malignant breast cells and tissues can express anomalous forms of PR transcripts. We have isolated four variant PR mRNAs that contain precise deletions of exons encoding sections of the DNA- and hormone-binding domains. The transcripts lack exon 2 (PRdelta2), exon 4 (PRdelta4), exon 6 (PRdelta6), or exons 5 and 6 (PRdelta5,6). On immunoblots, PRdelta4, delta6. and delta5, 6 cloned into the background of the PR A-isoform comigrate with similar proteins present in breast tumor extracts; delta6 and delta5, 6 are dominant-negative transcriptional inhibitors of wild-type A- and B-receptors. We propose that expression of variant PR can compromise the accuracy of receptor measurements as markers of hormone-dependent cancers, and can modify the responses of tumors to progestin therapies. |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 19% |
| Student > Ph. D. Student | 3 | 19% |
| Student > Bachelor | 2 | 13% |
| Professor > Associate Professor | 2 | 13% |
| Student > Master | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 4 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 5 | 31% |
| Biochemistry, Genetics and Molecular Biology | 2 | 13% |
| Medicine and Dentistry | 2 | 13% |
| Immunology and Microbiology | 1 | 6% |
| Veterinary Science and Veterinary Medicine | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 5 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2022.
All research outputs
#7,463,719
of 22,818,766 outputs
Outputs from Breast Cancer Research and Treatment
#1,658
of 4,658 outputs
Outputs of similar age
#9,983
of 32,945 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#4
of 19 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,658 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 32,945 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.